Clinical Safety of Current Available and Investigational ICIS for NSCLC

Target Audience
Oncology physicians, nurse practitioners, physician assistants; pulmonary physicians, nurse practitioners, physician assistants; pathologists and pharmacists.

Program Overview
Despite advances in the treatment of non-small cell lung cancer (NSCLC), overall 5-year survival has not significantly improved in recent years. Newly approved and emerging immune checkpoint inhibitor (ICI) therapies offer improvements in survival over chemotherapy alone, but toxicities and immune-related adverse events (irAEs) must be anticipated and managed for successful treatment. In this educational activity, faculty members review the role of PD-L1 testing to determine the best approach to ICI therapy, current efficacy and safety data for ICI therapies in NSCLC, and how to identify and mitigate irAEs. They evaluate clinical trial data, along with patient- and disease-related factors, that allow for the individualization of therapy selection to promote optimal patient outcomes.

Learning Objectives
Upon completion of this activity, participants should be better able to:

IMPLEMENT evidence-based and guideline-directed strategies to accurately identify and mitigate irAEs associated with ICI therapy